Oculis (NASDAQ:OCS) Sets New 52-Week Low – Should You Sell?

Oculis Holding AG (NASDAQ:OCS)’s stock price hit a new 52-week low during trading on Saturday . The company traded as low as $10.50 and last traded at $10.56, with a volume of 226612 shares. The stock had previously closed at $11.31.

Analysts Set New Price Targets

Several analysts have recently issued reports on OCS shares. HC Wainwright restated a “buy” rating on shares of Oculis in a research report on Tuesday, August 25th. Robert W. Baird lowered their price target on shares of Oculis from $49.00 to $38.00 and set an “outperform” rating for the company in a report on Monday, June 1st. Guggenheim dropped their price target on Oculis from $75.00 to $45.00 and set a “buy” rating for the company in a research report on Monday, June 1st. JPMorgan Chase & Co. reduced their price objective on Oculis from $23.00 to $20.00 and set an “overweight” rating on the stock in a research note on Friday, August 14th. Finally, Stifel Nicolaus decreased their price objective on Oculis from $50.00 to $40.00 and set a “buy” rating on the stock in a research report on Monday, June 1st. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Oculis currently has an average rating of “Moderate Buy” and a consensus target price of $38.00.

Oculis Stock Performance

The company has a debt-to-equity ratio of 0.01, a current ratio of 8.35 and a quick ratio of 8.35. The firm has a fifty day moving average price of $12.38 and a two-hundred day moving average price of $19.62. The stock has a market capitalization of $612.27 million, a PE ratio of -6.07 and a beta of 0.52.

Oculis (NASDAQ:OCS) last posted its quarterly earnings data on Tuesday, June 30th. The company reported ($0.20) earnings per share (EPS) for the quarter. Oculis had a negative net margin of 6,777.18% and a negative return on equity of 42.61%. The business had revenue of $0.38 million for the quarter. Research analysts expect that Oculis Holding AG will post -2.01 EPS for the current year.

Institutional Trading of Oculis

A number of large investors have recently made changes to their positions in OCS. Koshinski Asset Management Inc. purchased a new position in Oculis in the 1st quarter worth about $238,000. Millennium Management LLC bought a new position in Oculis in the 4th quarter worth about $312,000. Himension Capital Singapore PTE. LTD. bought a new position in Oculis in the 1st quarter worth about $503,000. Marshall Wace LLP purchased a new position in shares of Oculis during the second quarter worth approximately $393,000. Finally, Renaissance Technologies LLC purchased a new position in shares of Oculis during the fourth quarter worth approximately $499,000. 22.30% of the stock is owned by hedge funds and other institutional investors.

About Oculis

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.